Enterprise Therapeutics Limited

Sperimentazioni cliniche corrispondenti

Studio sull’Efficacia e Sicurezza di ETD001 Inalato in Persone con Fibrosi Cistica

Arruolamento concluso

2 1
Malattie in studio:
- Fibrosi cistica
Farmaci in studio:
- 3-Amino-N-{[5-[4-[Bis[(2S,3R,4R,5R)-2,3,4,5,6-Pentahydroxyhexyl]Amino]Piperidine-1-Carbonyl]-1,3-Diethyl-Benzimidazol-1-Ium-2-Yl]Methyl}-5H-Pyrrolo[2,3-B]Pyrazine-2-Carboxamide Dihydrochloride Chloride